Influenza vaccines: What do we want and how can we get it?

Advances in Experimental Medicine and Biology

Volumn 780, Issue , 2011, Pages 161-174

  Geeraedts, Felix ^a   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; AS 03; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; IC 31; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; MIFAMURTIDE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CONFERENCE PAPER; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG FORMULATION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; B-LYMPHOCYTES; CYTOKINES; DETERGENTS; DISEASE OUTBREAKS; EUROPE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; TH1-TH2 BALANCE; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 80053596320     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-5632-3_13     Document Type: Conference Paper

References (64)

1. Stohr K, Kieny MP, Wood D (2006) Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Nat Rev Microbiol 4:565-566 (Pubitemid 44317018)
2. Johnson NP, Mueller J (2002) Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76:105-115
3. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. Writing committee of the WHO Consultation on clinical aspects of pandemic (H1N1) 2009 Influenza. N Engl J Med 362:1708-1719
4. Taubenberger JK, Morens DM (2008) The pathology of influenza virus infections. Annu Rev Pathol 3:499-522 (Pubitemid 351488291)
5. Rothbarth PH, Groen J, Bohnen AM, de Groot R, Osterhaus AD (1999) Influenza virus serol-ogy-a comparative study. J Virol Methods 78:163-169 (Pubitemid 29117285)
6. Roman E, Miller E, Harmsen A, Wiley J, Von Andrian UH, Huston G, Swain SL (2002) CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 196:957-968
7. Boon AC, Fringuelli E, Graus YM, Fouchier RA, Sintnicolaas K, Iorio AM, Rimmelzwaan GF, Osterhaus AD (2002) Influenza A virus specific T cell immunity in humans during aging. Virology 299:100-108 (Pubitemid 35007515)
8. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939
9. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437:889-893 (Pubitemid 41486764)
10. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:2605-2615
11. http://www.who.int/csr/disease/avian-influenza/country/ cases-table-2011-05-13/en/index. html (access May 20, 2011)
12. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr (2007) Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 13:1348-1353 (Pubitemid 47510296)
13. Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194(Suppl 2):S111-S118 (Pubitemid 44630954)
14. Wood JM, Williams MS (1998) History of inactivated influenza vaccines. In: Nicholson KG, Webster RG, Hay AJ (eds) Textbook of Influenza. Blackwell Science, Oxford, pp 317-323
15. Ehrlich HJ, Miiller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pollabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358:2573-2584 (Pubitemid 351831358)
16. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Bruhl P, Kreil TR, Ehrlich HJ, Barrett PN (2010) A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 5:e9349
17. Vajo Z, Tamas F, Sinka L, Jankovics I (2010) Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 375:49-55
18. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, mul-ticentre study. Brit Med J 340:c2649. doi:10.1136/bmj.c2649
19. Leroux-Roels G (2009) Pre-pandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 9:1057-1071
20. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol Basel 115:63-73
21. Beyer WE, Palache AM, Osterhaus AD (1998) Comparison of serology and reactogenicity between influenza sub-unit vaccines and whole virus or split vaccines: a review and metaanalysis of the literature. Clin Drug Investig 15:1-12 (Pubitemid 28073487)
22. Nicholson KG, Tyrrell DA, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG (1979) Clinical studies of monovalent inactivated whole virus and sub-unit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7:123-136 (Pubitemid 9149059)
23. Stephenson I, Nicholson KG, Gliick R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC (2003) Safety and antigenicity of whole virus and sub-unit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362:1959-1966 (Pubitemid 37548419)
24. http://www.who.int/vaccine-research/diseases/influenza/flu-trials-tables/ en (access May 20, 2011)
25. Hovden AO, Cox RJ, Madhun A, Haaheim LR (2005) Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 62:342-352 (access May 20, 2011) (Pubitemid 41565386)
26. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26:2350-2359
27. Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W (2008) Head-to-head comparison of four nonadju-vanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26:6555-6563
28. Hovden AO, Cox RJ, Haaheim LR (2005) Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 62:36-44 (Pubitemid 41025876)
29. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A (2008) Whole inactivated virus influenza vaccine is superior to sub-unit vaccine in inducing immune responses and secretion of pro-inflammatory cytokines by DCs. Influenza Other Respi Viruses 2:41-51
30. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signaling. PLoS Pathog 4:e1000138
31. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981-990 (Pubitemid 44518965)
32. Saurwein-Teissl M, Zisterer K, Schmitt TL, Gliick R, Cryz S, Grubeck-Loebenstein B (1998) Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while sub-unit vaccines support T cell proliferation. Clin Exp Immunol 114:271-276 (Pubitemid 28505729)
33. Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, Sakurai K, Coban C, Horii T, Akira S, Ishii KJ (2010) Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2:25ra24
34. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, Belardelli F (2002) Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169:375-383 (Pubitemid 34686158)
35. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type I inter-ferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-170
36. Coro ES, Chang WL, Baumgarth N (2006) Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 176:4343-4351 (Pubitemid 44264414)
37. Chang WL, Coro ES, Rau FC, Xiao Y, Erle DJ, Baumgarth N (2007) Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol 178:1457-1467 (Pubitemid 46154617)
38. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531 (Pubitemid 38314425)
39. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537 (Pubitemid 34441357)
40. Barr TA, Brown S, Mastroeni P, Gray D (2009) B cell intrinsic MyD88 signals drive IFN- gamma production from T cells and control switching to IgG2c. J Immunol 183:1005-1012
41. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ (2007) TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 178:2182-2191 (Pubitemid 46233416)
42. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G (2005) Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 174:4043-4050 (Pubitemid 40395980)
43. Miyaki C, Quintilio W, Miyaji EN, Botosso VF, Kubrusly FS, Santos FL, Iourtov D, Higashi HG, Raw I (2010) Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 28:2505-2509
44. Skountzou I, Martin MP, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103-4112
45. Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sata T, Kurata T, Hasegawa H (2006) Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8:2706-2714 (Pubitemid 44692546)
46. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K (2008) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26:3461-3468
47. http://www.intercell.com/main/forvaccperts/products/ic31R-seasonal- influenza-vaccine (accessed May 20, 2011)
48. Eickhoff TC, Myers M (2002) Workshop summary. aluminum in vaccines. Vaccine 20(Suppl 3):S1-S4
49. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287-293
50. Keitel WA, Atmar RL (2009) Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 333:431-451
51. http://www.who.int/vaccine-research/diseases/influenza/flu-trials-tables/ en/index.html (accessed May 20, 2011)
52. http://ecdc.europa.eu/en/healthtopics/documents/0911-pandemic-influenza- (h1n1)-qa-on- vaccines-and-vaccination-experts.pdf (accessed May 20, 2011)
53. Ninomiya A, Imai M, Tashiro M, Odagiri T (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554-3560 (Pubitemid 46575102)
54. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209-3222
55. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943 (Pubitemid 32568336)
56. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza /Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191:1210-1215
57. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59- adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4:e4384
58. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2:15ra5
59. Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331-3334
60. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT (2009) MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 26:1477-1485
61. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG (2009) Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27:4187-4195
62. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F (2009) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106:3877-3882
63. Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T (2010) Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 15:pii: 19561
64. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3:e1401